---
title: "Tevogen Bio Holdings (now Tevogen) delays 10-K"
url: "https://aibio.space/news/tevogen-bio-holdings-now-tevogen-delays-10-k-sees-2024-loss-about-13-7/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-04-01"
section: "Distress"
tickers: "NASDAQ:TVGN"
source: "https://www.sec.gov/Archives/edgar/data/1860871/000164117225001996/formnt10-k.htm"
summary: "Tevogen said a change in outside accounting providers in September 2024 left it needing more time. It will keep reporting material weaknesses in internal c"
---

By the aibio.space news desk.

Sources

- [Tevogen Inc. NT 10-K (2025-04-01)](https://www.sec.gov/Archives/edgar/data/1860871/000164117225001996/formnt10-k.htm)

[TVGN](https://aibio.space/companies/tevogen/)

2025-04-01

# Tevogen Bio Holdings (now Tevogen) delays 10-K, sees 2024 loss of about $13.7 million

Tickers [TVGN](https://aibio.space/companies/tevogen/)

Tevogen said a change in outside accounting providers in September 2024 left it needing more time. It will keep reporting material weaknesses in internal controls.

## Key facts

- **Company**: Tevogen Inc. (NASDAQ: TVGN)

- **News type**: Distress

- **Primary source**: [Tevogen Inc. NT 10-K (2025-04-01)](https://www.sec.gov/Archives/edgar/data/1860871/000164117225001996/formnt10-k.htm)

*A columned courthouse. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.*

Tevogen Bio Holdings Inc. (now Tevogen Inc.) said on April 1, 2025, that it could not file its Annual Report on Form 10-K for the year ended December 31, 2024, by the due date.

The Warren, New Jersey company filed a Form 12b-25, a notification of late filing that gives a short automatic extension. Tevogen said it outsources part of its internal accounting and financial reporting to a third party and changed service providers in September 2024. It needs more time to finalize its financial statements and notes. The company said it will continue to report material weaknesses related to its internal controls over financial reporting in the 10-K.

Tevogen expects to file as soon as practicable and within the 15 calendar day extension period.

The company gave preliminary, unaudited figures. It expects a net loss of approximately $13.7 million for 2024, compared with approximately $60.5 million for 2023. The 2024 loss mainly reflects a $53.6 million loss from operations, largely non-cash stock-based compensation. That expense arose when a liquidity event condition in certain stock awards was satisfied at the closing of a business combination on February 14, 2024. It also includes $7.5 million in transaction costs. Those were partly offset by a $48.5 million change in the fair value of convertible promissory notes.

Tevogen said actual results may vary significantly from these expectations. The notice is available as a [Form NT 10-K](https://www.sec.gov/Archives/edgar/data/1860871/000164117225001996/formnt10-k.htm).

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

TVGN

Tevogen Inc.

NASDAQ · United States

Open the starter desk

## More in Distress

Distress

### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/)

Oct 29, 2026

Distress

### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/)

Oct 29, 2026

Distress

### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/)

Oct 28, 2026

---
Source page: https://aibio.space/news/tevogen-bio-holdings-now-tevogen-delays-10-k-sees-2024-loss-about-13-7/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Tevogen Bio Holdings (now Tevogen) delays 10-K", 2025-04-01, https://aibio.space/news/tevogen-bio-holdings-now-tevogen-delays-10-k-sees-2024-loss-about-13-7/